USPTO serial 90801633
NEOGENOMICS EUROPE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WOLD, BARBARA NIELSEN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEOGENOMICS EUROPE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anessa O. Kramer
Anessa O. Kramer Honigman LLP39400 Woodward Avenue, Suite 101Bloomfield Hills, MI 48304-5151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pre-packaged medical tests kits to aid in the diagnosis of disease or cancer, namely, kits primarily composed of clinical medical reagents and assays for use in disease testing for clinical medical laboratory use | ACTIVE | — |
| 010 | Pre-packaged medical tests kits to aid in the diagnosis of disease or cancer, namely, kits primarily composed of DNA probes for use in disease testing for clinical medical laboratory use | ACTIVE | — |
| 042 | Medical research; genetic mapping for scientific purposes, namely, gene sequencing; genetic testing and sequencing for scientific research purposes; molecular sequencing for scientific research purposes; cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells all being for scientific purposes; clinical study and testing of cells for scientific or research purposes; medical and scientific research information in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells; medical and scientific research in the field of gene sequencing, molecular sequencing, cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells, and cancer; providing scientific information to others in the fields of oncology, pathology and gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells scientific testing and research services and clinical scientific testing; providing an internet website portal featuring gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells for scientific purposes; scientific and medical research information in the fields of scientific testing and research services, medical research services, and clinical scientific testing; providing cloud-based scientific and medical research information in the nature of providing temporary use of non-downloadable cloud based software for providing information to others in the field of scientific testing and research services, medical research services, and clinical scientific testing; providing temporary use of online non-downloadable software for analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information and pertaining to such testing and analysis; software as a service (SAAS) services featuring software for analysis of medical test results; non-downloadable computer software for analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information pertaining to testing and analysis; providing medical research and scientific research information in the field of oncology; scientific testing and research services in the field of human disease and human medical conditions; providing medical research services in the field of human disease and human medical conditions; providing clinical scientific testing services and medical research and testing for research purposes in the field of human disease and human medical conditions; clinical laboratory research services, oncology reference laboratory services for research and scientific purposes, providing medical research information and interactive scientific research information to others in the fields of medical tests, medical testing, medical research, pathology, diagnostic testing, oncology testing and human disease and medical conditions; providing cloud-based information in the nature of providing temporary use of non-downloadable cloud based software for providing information to others to others in the field of scientific testing and research, medical research, and clinical scientific testing; providing online non-downloadable Internet-based software for medical testing and analysis of medical test results; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; medical and scientific research, namely, conducting clinical trials for others; conducting research and clinical trials for others relating to medical devices and pharmaceuticals; software as a service (SAAS) services featuring software for use in nucleic acid and protein assay analysis and for quality control, clinical decision support, validation, interpretation, reporting, data management, integration with medical records, physician portals, laboratory networking, professional healthcare and trial matching services all related to genomic analysis and molecular analysis; providing temporary use of cloud-based non-downloadable computer software providing medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services, and medical testing for diagnostic or treatment purposes | ACTIVE | — |
| 044 | Medical diagnostic testing services in the field of human disease and human medical conditions; medical testing for diagnostic or treatment purposes; providing medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services and medical testing for diagnostic or treatment purposes; providing an Internet website portal featuring medical information in the field of human disease, and human medical conditions, medical diagnostic testing services, medical testing for diagnostic or treatment purposes; providing cloud-based medical information to others in the field of human disease, human medical conditions, medical diagnostic testing services, and medical testing for diagnostic or treatment purposes; medical testing for the detection of cancer; medical testing for the detection of genetic information pertaining to human disease; medical diagnostic testing to aid in diagnosis, prognosis and therapy selection; oncology reference laboratory services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NeoGenomics Laboratories, Inc.
- Other trademarks owned by NeoGenomics Laboratories, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NEOGENOMICS EUROPE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 18, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 18, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 12, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 10, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 10, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 10, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 14, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 1, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 1, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 1, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 20, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 20, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 30, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 16, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 27, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 27, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 13, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 28, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 28, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 28, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 11, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 2, 2021 | NWAP | NEW APPLICATION ENTERED | — |